本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 公司首次公开发行后，总股本为93,161,111股。 2022年12月22日，公司2021年股票期权激励计划第一个行权期完成行权，共62人行权，公司向激励对象 定向发行公司A股普通股361,862股。本次行权后，公司总股本由 93,161,111 股变更为93,522,973股。 重要内容提示： ●本次股票上市类型为其他；股票认购方式为网下，上市股数为434,236股。 本次股票上市流通总数为434,236股。 ●本次股票上市流通日期为2025年12月22日。 一、本次上市流通的限售股类型 2022年9月1日，根据中国证券监督管理委员会《关于同意江苏康为世纪生物科技股份有限公司首次公开 发行股票注册的批复》（证监许可〔2022〕2003号），同意江苏康为世纪生物科技股份有限公司（以下 简称"公司"）首次公开发行股票的注册申请。公司首次向社会公开发行人民币普通股（A股） 23,290,278股，并于2022年10月25日在上海证券交易所科创板上市交易。首次公开发行股票完成后，公 ...

证券代码：688426 证券简称：康为世纪 公告编号：2025-044 江苏康为世纪生物科技股份有限公司 关于首次公开发行前股票期权行权限售股上市流通的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●本次股票上市类型为其他；股票认购方式为网下，上市股数为434,236股。 本次股票上市流通总数为434,236股。 二、本次上市流通的限售股形成后至今公司股本数量变化情况 公司首次公开发行后，总股本为93,161,111股。 2022年12月22日，公司2021年股票期权激励计划第一个行权期完成行权，共62人行权，公司向激励对象 定向发行公司A股普通股361,862股。本次行权后，公司总股本由 93,161,111 股变更为93,522,973股。 2023年5月16日，公司2022年年度股东大会审议通过2022年度权益分派方案，以资本公积金转增股本方 式向全体股东每10股转增2股，转增后，公司总股本由93,522,973股转增为112,227,568股。 2024年3月11日，2021年股票期权激励计 ...

Group 1 - The company Kangwei Century (SH 688426) announced that approximately 434,200 restricted shares will be unlocked and available for trading on December 22, 2025, representing 0.386% of the total share capital [1] - For the year 2024, the company's revenue will be entirely derived from the molecular diagnostics industry, accounting for 100.0% of its business [2] - As of the latest report, the market capitalization of Kangwei Century is 2.8 billion yuan [3]

证券代码：688426 证券简称：康为世纪 公告编号：2025-044 江苏康为世纪生物科技股份有限公司 关于首次公开发行前股票期权行权限售股上市流通的公告 ●本次股票上市类型为其他；股票认购方式为网下，上市股数为434,236股。 本次股票上市流通总数为434,236股。 ●本次股票上市流通日期为2025 年 12 月 22 日。 一、本次上市流通的限售股类型 2022 年 9 月 1 日，根据中国证券监督管理委员会《关于同意江苏康为世纪生 物科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕2003 号）， 同意江苏康为世纪生物科技股份有限公司（以下简称"公司"）首次公开发行股票的 注册申请。公司首次向社会公开发行人民币普通股（A 股）23,290,278 股，并于 2022 年 10 月 25 日在上海证券交易所科创板上市交易。首次公开发行股票完成后， 公司总股本为 93,161,111 股。其中有限售条件流通股 73,115,709 股，无限售条件流 通股 20,045,402 股。具体情况详见公司于 2022 年 10 月 24 日在上海证券交易所网 站（www.sse.com.cn ...

中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为江苏康 为世纪生物科技股份有限公司（以下简称"康为世纪"或"公司"）首次公开发 行股票并在科创板上市及后续持续督导保荐人，根据《中华人民共和国公司法》 《中华人民共和国证券法》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上海证券交易所科创板股票上市规则》等有关法律法规和规 范性文件的要求，对公司首次公开发行前股票期权行权限售股上市流通的事项进 行了核查，核查情况及核查意见如下： 中信证券股份有限公司 关于江苏康为世纪生物科技股份有限公司 首次公开发行前股票期权行权限售股上市流通的核查意见 一、本次上市流通的限售股类型 2022 年 9 月 1 日，根据中国证券监督管理委员会《关于同意江苏康为世纪 生物科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕2003 号），同意江苏康为世纪生物科技股份有限公司（以下简称"公司"）首次公开 发行股票的注册申请。公司首次向社会公开发行人民币普通股（A 股）23,290,278 股，并于 2022 年 10 月 25 日在上海证券交易所科创板上市交易。首次公开发行 股票完成后 ...

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Views - The pharmaceutical and biotechnology sector saw a weekly increase of 2.67%, underperforming the Wind All A index (2.9%) but outperforming the CSI 300 index (1.64%). The raw material drug sector experienced a decline of 4.27%, while chemical preparations and pharmaceutical circulation products increased by 4.18% and 3.71%, respectively [3][8] - Recent policies in Shanghai and Beijing aim to support the high-quality development of the medical device industry, indicating a shift towards innovation and global competitiveness in this sector. The report suggests monitoring the transformation progress of leading companies in the medical device field [3][12] - Flu activity is on the rise, with the percentage of flu-like cases reported by sentinel hospitals in southern provinces reaching 7.8%, up from 6.8% the previous week, and higher than the same period in 2022 and 2024 [3][11] Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector increased by 2.67% from November 24 to November 28, 2025, with raw material drugs declining by 4.27% and chemical preparations increasing by 4.18% [8][9] - Individual stock performances included significant gains for Haiwang Biological (38.2%), Yue Wannianqing (36.2%), and Guangji Pharmaceutical (31.7%), while *ST Changyao (-15.3%), Huitai Medical (-9.6%), and Kangwei Century (-8.8%) saw notable declines [11] Industry News and Key Company Announcements Important Industry Events - The report highlights the increase in flu-like illness percentages in both southern (7.8%) and northern (8.6%) provinces, indicating a significant rise in flu activity compared to previous years [11][12] Industry News - Significant approvals were noted, including the NMPA's approval of Xinmeiyue® for treating moderate to severe plaque psoriasis and the FDA's accelerated approval of Sibeprenlimab for IgAN treatment [12][14] Company Announcements - Notable announcements include the FDA approval of a generic injectable drug by Jianyou Co. and the successful completion of a Phase III trial for JS001sc, a subcutaneous PD-1 monoclonal antibody for non-small cell lung cancer [15][16]

Market Overview - The medical device sector increased by 1.13% on November 28, with Kangwei Century leading the gains [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] Top Performers - Kangwei Century (688426) closed at 27.86, up 5.17% with a trading volume of 18,500 lots and a transaction value of 50.42 million [1] - Mindray Medical (300760) closed at 204.01, up 3.93% with a trading volume of 117,800 lots and a transaction value of 2.378 billion [1] - Yingke Medical (300677) closed at 43.07, up 3.71% with a trading volume of 179,300 lots and a transaction value of 761 million [1] Underperformers - Weigao Orthopedics (688161) closed at 29.15, down 2.57% with a trading volume of 14,700 lots and a transaction value of 43.07 million [2] - Danna Biological (920009) closed at 81.75, down 2.21% with a trading volume of 8,252 lots and a transaction value of 67.67 million [2] - Zhonghong Medical (300981) closed at 14.21, down 2.07% with a trading volume of 86,200 lots and a transaction value of 122 million [2] Capital Flow - The medical device sector experienced a net outflow of 173 million from institutional investors, while retail investors saw a net inflow of 15.56 million [2] - The top stocks by net inflow from retail investors included Mindray Medical and Hotgen Biotech, while Zhendong Medical and Haier Biomedical saw significant net outflows [3]

Group 1 - The core viewpoint of the news is that Jiangsu Kangwei Century Biotechnology Co., Ltd. has seen a stock price increase of 5.13%, reaching 27.85 CNY per share, with a total market capitalization of 3.133 billion CNY [1] - The company was established on September 3, 2010, and went public on October 25, 2022, focusing on the research, production, and sales of molecular detection products, with 89.14% of its revenue coming from product sales [1] - The trading volume for the stock was 39.9693 million CNY, with a turnover rate of 3.88% [1] Group 2 - Among the top ten circulating shareholders, the fund under Yuanxin Yongfeng has increased its holdings in Kangwei Century by 277,200 shares, now holding a total of 950,000 shares, which represents 2.5% of the circulating shares [2] - The Yuanxin Yongfeng Medical Health A fund has achieved a year-to-date return of 35.33%, ranking 1785 out of 8127 in its category [2] - The fund has a total scale of 387 million CNY and has generated a floating profit of approximately 1.292 million CNY from its recent investment [2]

Core Points - Kangwei Century (688426.SH) closed at 26.49 yuan, with a decline of 4.71%, currently in a state of breaking issue [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 25, 2022, with an initial offering price of 48.98 yuan per share [1] - The total number of shares publicly issued was 23,290,278, accounting for 25% of the total share capital after issuance [1] - The total funds raised amounted to 1,140.76 million yuan, with a net amount of 1,054.30 million yuan after deducting issuance costs, exceeding the original plan by 68.63 million yuan [1] - The funds are intended for projects including the industrialization of medical devices and biological testing reagents, marketing network construction, molecular detection product R&D, and working capital supplementation [1] Financial Details - The issuance costs totaled 86.45 million yuan, with CITIC Securities receiving underwriting fees of 64.49 million yuan [2] - CITIC Securities Investment Co., Ltd., a related subsidiary involved in the underwriting, was allocated 931,611 shares, representing 4.00% of the total shares issued [2] - On June 6, 2023, the company announced a dividend plan of 5.2 yuan (pre-tax) per 10 shares, with a bonus issue of 2 shares [2]

Group 1 - The core point of the news is that Kangwei Century (688426) has seen a net financing purchase of 205.72 million yuan on November 26, 2025, with a total financing balance of 1.32 billion yuan, indicating a positive trend in investor interest [1][2][3] - In the last three trading days, the company has recorded a cumulative net purchase of 1,312.92 million yuan, suggesting sustained investor confidence [1] - Over the past 20 trading days, there have been 12 days with net financing purchases, highlighting a consistent demand for the company's stock [1] Group 2 - On November 26, 2025, the net financing purchase was 205.72 million yuan, with a financing balance of 1.32 billion yuan, representing 12.49% of the circulating market value [2] - The financing balance increased by 1.58% compared to the previous day, indicating a growing interest in the stock [3] - The financing balance has shown fluctuations over the past few days, with notable increases on November 25 (896.86 million yuan) and November 21 (402.56 million yuan) [2][3]